The Global Oxytocic Pharmaceutical Market is anticipated to rise at a value CAGR of 11.9% over 2019-2028. According to a study published by Insure Insights on the Oxytocic Pharmaceutical Market, Oxytocin drugs are used to induce the level of hormone that is used to induce labor or strengthen uterine contractions and can be also be used to control bleeding after childbirth. Oxytocin is also used in stimulating uterine contractions in a woman with an incomplete or threatened miscarriage. There has been a significant rise in the cases of pregnancy-related complications, and an increase in the per capita income is driving the market growth.

Top Driver: Increase in the number of caesarian procedures worldwide is driving the market

A routine administration of Oxytocic drugs is essential after caesarian delivery as it is helpful in reducing the risk of excessive bleeding and is commonly used in developing countries to control bleeding. There has been a remarkable growth in the incidence of preterm births, and significant growth of labor induction is further enhancing the growth of the market. The increase in healthcare awareness among people and technological advances in the is boosting the market further

Postpartum Hemorrhage to Make Crucial Contribution to Growth of Global Oxytocic Pharmaceutical Market

The Postpartum Hemorrhage is the most common in women nowadays, intravenously oxytocin is given as a first line uterotonic drug as it is preferred in this case and is also more effective than other drugs and have fewer side effects as compared with other drugs. The rise in the cases of PPH is driving the global Oxytocic Market. Based on the Product type segment Abortion Induced Incomplete have dominated the market as there has been a significant increase in the rate of Abortion, Oxytocic drug very helpful if the Abortion is incomplete as they help in clearing the uterus completely, these drugs are even more effective in early pregnancy. In terms of End Use, Hospitals have dominated the market growth due to better healthcare facilities and also due to the availability of Technologically advanced surgeries in hospitals.

North America will continue to Rule the global Oxytocic Pharmaceutical Market

The rise in the cases of PPH globally and cases like Abortion Induced Incomplete are driving the growth in the region. It was estimated that about 42% off all unintended pregnancies end in Abortion, and over 92% of abortions are the result of unintended pregnancy in the US. Technological advances in the region, better healthcare infrastructure, rise in per capita income are expanding the growth of the market.  In addition to the rise in Government initiatives for women healthcare, R&D investments are further expanding market growth.

Strategic collaboration and acquisition, Joint venture Partnerships are the major strategies of the competitors

The global Oxytocic Pharmaceutical market is largely fragmented. The competitors are focused on new product launches, joint ventures, partnerships, acquisitions for the overall growth. The key competitors of the global Oxytocic Pharmaceutical market are Fresenius Kabi, Biofutura, Abbott Laboratories, JHP Pharmaceuticals LLC, Baxter Healthcare, Teva Pharmaceutical Industries, App Pharmaceuticals LLC, Pfizer, and Novartis AG.

Novartis AG: Novartis AG is a one of a major competitor of the Oxytocic Pharmaceutical market; In January 2020 Novartis AG had announced the acquisition with The Medicines Company, The acquisition was made by Novartis AG to expand its product portfolio in Cardiac Treatments

Pfizer: Pfizer, in July 2019 had announced the merger with Array BioPharma, Array is focused in developing cancer medicines this merging was done by Pfizer as it would expand Pfizer’s future revenue significantly. It had also strengthened the biopharmaceutical business of Pfizer. The deal of merging of Pfizer with Array was made for USD 11.4 billion

Fresenius Kabi: Fresenius Kabi, in the year 2019 had announced the acquisition with NxStage Medical, Inc. NxStage is involved in developing and producing, innovative medical devices for use in home dialysis and critical care, this acquisition was made by Fresenius Kabi to strengthen its business in dialysis products, services, and Care Coordination.

Scope of the Report

By Type

• Postpartum Hemorrhage
• Pre-eclampsia/Eclampsia
• Others

By Product Type

• Abortion Induced Incomplete
• Postpartum Hemorrhage
• Inevitable Abortion

By End-User

• Hospitals
• Clinics
• Maternity Center

By Region

• North America
• Europe
• Asia Pacific
• LAMEA